Lyka LabsBOM:500259 +0.78%60 Quick Ratio is 0.92 as of Mar. 2026, which is 96% above its 10-year median of 0.47. GuruFocus rates BOM:500259 with a GF Score™ of 60/100 and a GF Value™ of ₹127.26 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Lyka Labs ranks worse than 82.21% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Lyka Labs's quick ratio for the quarter that ended in Mar. 2026 was 0.92.
Lyka Labs has a quick ratio of 0.92. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Lyka Labs's Quick Ratio or its related term are showing as below:
BOM:500259'
s Quick Ratio Range Over the Past 10 Years
Min: 0.23 Med: 0.47 Max: 1.18
Current: 0.92
During the past 13 years, Lyka Labs's highest Quick Ratio was 1.18. The lowest was 0.23. And the median was 0.47.
BOM:500259's Quick Ratio is ranked worse than 82.21% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs BOM:500259: 0.92
Lyka Labs (BOM:500259) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lyka Labs Quick Ratio Related Terms
Lyka Labs Quick Ratio Historical Data
* Premium members only.
The historical data trend for Lyka Labs's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500259 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Lyka Labs's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lyka Labs's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Lyka Labs's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyka Labs (BOM:500259) has a Quick Ratio of 0.92 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lyka Labs and its competitors. This is 96% above median its historical median of 0.47. Over the past decade, Lyka Labs' Quick Ratio has ranged from 0.23 to 1.18. According to the industry distribution chart, Lyka Labs ranks #1160 out of 1411 companies in the Biotechnology industry, placing it in the top 82.2%.
Is Lyka Labs' Quick Ratio too high?
Lyka Labs' current Quick Ratio of 0.92 is 96% above median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 1.18. The Biotechnology industry median Quick Ratio is 3.59. Lyka Labs' value of 0.92 is 74.4% below this industry median. Based on the distribution chart, Lyka Labs ranks #1160 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lyka Labs has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #1160 out of 1411 companies for Quick Ratio. This places Lyka Labs in the lower half of its industry. The industry median Quick Ratio is 3.59. Lyka Labs' value of 0.92 is 74.4% below this benchmark. Historically, Lyka Labs' own Quick Ratio has ranged from 0.23 to 1.18 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 3.59, Lyka Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lyka Labs's current Quick Ratio of 0.92 is 74.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lyka Labs and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyka Labs's current Quick Ratio is 0.92, which is 96% above median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.26, compared to a current price of ₹72.36 — trading 43.1% below its estimated fair value. The current Quick Ratio is 0.92, which is 96% above median its 10-year median of 0.47 and 74.4% below the Biotechnology industry median of 3.59. Lyka Labs' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Quick Ratio is 0.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹72.36 is trading 43.1% below its estimated GF Value™ of ₹127.26.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
Quick Ratio: 0.92 (96% above median its 10-year median of 0.47)
GF Value™: ₹127.26 vs. price of ₹72.36 (43.1% below fair value)
Industry Position: 74.4% below the Biotechnology median (#1160 of 1411)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
60GF Score
Get the complete analysis for BOM:500259
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
